

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

ESTIMATED ANNUAL RESULTS FOR THE YEAR 2023 AND BUSINESS UPDATE

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended December 31, 2023 (the “**Reporting Period**”) and the latest information currently available to the Board, the Group is expected to record a revenue of RMB330 million to RMB340 million for the Reporting Period, representing an increase of approximately 31% to 36% as compared to RMB251 million for the year ended December 31, 2022. The increase in the revenue is mainly attributable to:

- (i) continued hospital penetration of our transcatheter aortic heart valve implantation (“**TAVI**”) products in the People’s Republic of China (“**China**”) that contributed to the rapid increase in implantation numbers and revenue. During the Reporting Period, our TAVI products newly entered 117 hospitals in China, representing an increase of approximately 27% in hospital coverage as compared to that of the year ended December 31, 2022. Our implantation numbers in China increased by approximately 45% during the Reporting Period as compared to that of 2022; and
- (ii) market expansion and revenue increase of our TAVI products overseas. As of December 31, 2023, our TAVI products have entered nearly a hundred hospitals in Argentina, Colombia, Thailand and Russia. During the Reporting Period, we have completed a total of 120 commercial TAVI cases overseas, representing an increase of approximately 90% as compared to that of 2022.

In addition, the Group has also focused on integrating advantageous resources and accelerating key self-developed projects: we have submitted the registration application of our third-generation TAVI product, VitaFlow® III to the National Medical Products Administration (國家藥品監督管理局) (“NMPA”); we have completed 10 compassionate uses for our transcatheter mitral valve replacement product, continued to push forward with the clinical follow up so as to accumulate clinical experience for the subsequent large-scale clinical trials of the product, and also initiated type testing at the same time; and our left atrial appendage closure product, AnchorMan®, has obtained the registration approval issued by the NMPA and the production license issued by the local medical regulatory authorities.

During the Reporting Period, the Group actively implemented resource focusing and cost control measures, continuously reduced production costs and enhanced operational efficiency. In the future, we will prioritize the health of our financial statements and further reduce losses by focusing on business, increasing revenue, saving costs and reducing expenses, and strive to achieve breakeven as soon as possible while maintaining steady revenue growth.

The data contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts and relevant revenue estimates of the Group for the year ended December 31, 2023 made available to the Board as of the date of this announcement, which have not been audited or reviewed by the Company’s auditors nor reviewed by the audit committee of the Company, and the actual financial results of the Group for the year ended December 31, 2023 may be subject to adjustments. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended December 31, 2023 which is expected to be published in March 2024.

Shareholders and potential investors are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, February 28, 2024

As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.